The Initial MND Patient who started in September would be well into the escalating dose period now.
With no mention from the DSMB we can take it that the escalating dose has not manifested any major adverse effects.
PAA Management will need to craft the ASX Announcements going forward with as much commercial detail as possible to impart the reduction in risk and that having GMP Grade MPL Tablets in stock with a comprehensive understanding of Cost of Manufacture and have also logistical experience now in moving MPL Tablets around the world.
The Tablets have also undergone extensive stabilization testing and have shown they have lasting characteristics.
K9 Updates may well be the first 2023 update with multiple enrolled dogs completing the trial...
Plenty on the agenda to promote and that should deliver the Catalysts required to incrementally increase the SP for early 2023.
The Initial MND Patient who started in September would be well...
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.3¢ |
Change
-0.008(4.17%) |
Mkt cap ! $83.90M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.3¢ | $59.77K | 338.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 376984 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 25091 | 2 |
View Market Depth
| Last trade - 15.42pm 13/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |